Lucentis Cost: Now the Cheapest Branded Eye Injection, at $131.92 a Dose
Lucentis used to be one of the expensive ones. Its Medicare payment limit has fallen 60% during 2026, and the drug in a standard 0.5 mg injection is now allowed $131.92, against $1,444.50 for Eylea and $1,879.32 for Vabysmo. Your 20% on a full visit is $49.23. The strange part: both of its biosimilars now cost Medicare more than the brand.
- Lucentis bills under J2778 at $26.384 per 0.1 mg. Wet macular degeneration uses 0.5 mg, so 5 units. Diabetic macular edema and diabetic retinopathy use 0.3 mg, so 3 units.
- A year in one eye is roughly $295 in Part B coinsurance, against about $1,870 for Eylea and $2,392 for Vabysmo. That is the largest gap between branded options in this drug class.
- Byooviz, a ranibizumab biosimilar, is allowed $249.493 per unit against the brand's $26.384. If you were switched to a biosimilar for cost reasons, that is now backwards. Ask the office which product they bill.
What One Lucentis Injection Is Allowed
Part B pays off a payment limit CMS republishes every quarter (average sales price plus 6%). These are the limits in force October 1 through December 31, 2026, in a retina practice's own office.
| Line item | Wet AMD, 0.5 mg | Diabetic eye disease, 0.3 mg |
|---|---|---|
| Billing code | J2778 | J2778 |
| Payment limit per 0.1 mg | $26.384 | $26.384 |
| Units on a correct claim | 5 | 3 |
| Drug allowed | $131.92 | $79.15 |
| Injection, CPT 67028 (office) | $114.23 | $114.23 |
| Total allowed, one eye | $246.15 | $193.38 |
| Your 20% on Original Medicare | $49.23 | $38.68 |
Source: CMS October 2026 Medicare Part B payment limit file (2Q26 ASP data) and the 2026 physician fee schedule (CPT 67028, 3.42 non-facility RVUs at the $33.4009 conversion factor). Notice that at this price the injection now costs more than the drug, which is true of nothing else in the class.
Want to know what your Lucentis (ranibizumab) eye injection should cost you?
Costs vary substantially by procedure, location, facility, and insurance. Get a personalized estimate based on your situation.
Already have a bill? Send it to CareRoute and we will work to reduce it. 64% of cases reduced.
Why the Price Fell 60% in One Year
A Part B payment limit is not a list price. It tracks what the drug actually sells for in the market, recalculated every quarter from manufacturer-reported average sales price. As ranibizumab lost volume to Eylea, Vabysmo, and its own biosimilars, its reported selling price collapsed, and the limit followed:
| Quarter, 2026 | J2778 per 0.1 mg | Drug cost, 0.5 mg dose |
|---|---|---|
| January | $65.443 | $327.22 |
| April | $67.853 | $339.27 |
| July | $51.090 | $255.45 |
| October (current) | $26.384 | $131.92 |
Two practical consequences. First, this moves again on January 1, 2027, so check the current quarter before relying on a number. Second, if you were billed for a Lucentis injection earlier in the year, your coinsurance was legitimately higher then, which is not an error.
Both Ranibizumab Biosimilars Now Cost More Than the Brand
Biosimilars exist to undercut the originator. In the current Medicare file, these two do not, because the brand's price fell faster than theirs:
| Product | Limit per 0.1 mg | 0.5 mg dose + shot | Your 20% |
|---|---|---|---|
| Lucentis, brand (J2778) | $26.384 | $246.15 | $49.23 |
| Cimerli, biosimilar (Q5128) | $81.130 | $519.88 | $103.98 |
| Byooviz, biosimilar (Q5124) | $249.493 | $1,361.70 | $272.34 |
What to ask, and who to ask
Ask the retina practice, not the manufacturer: "Which ranibizumab product are you billing for me, and is the brand an option?" Practices pick among these partly on acquisition cost and partly on contract, and moving between ranibizumab products is a much smaller clinical question than moving between drug classes. On a statement, the code tells you which one you got: J2778 is the brand, Q5128 is Cimerli, Q5124 is Byooviz.
Checking a Lucentis Bill
- Units: 5 for a 0.5 mg wet AMD dose, 3 for a 0.3 mg diabetic dose, per eye. A claim for 50 units is a decimal error worth about $1,187.
- Eye modifier: CPT 67028 once per eye, with RT or LT, or modifier 50 if both eyes were injected at the same visit. A one-eye visit billed as two is common and doubles everything.
- Which code: J2778, Q5124, and Q5128 are three different prices for the same molecule. Make sure the code on the claim matches the product you were actually given.
- No waste line: ranibizumab comes in single-dose vials and prefilled syringes, so there is normally nothing discarded and no JW modifier charge.
The full walkthrough of a drug-plus-administration bill is in our infusion bill guide.
Two Things That Change the Total
Where the shot is given
The drug costs the same anywhere. In the practice's own office the injection is allowed $114.23 and that is the whole non-drug charge. In a hospital outpatient department the physician's portion drops to $75.49 and the hospital adds a facility fee on top, usually the bigger number. At Lucentis prices the facility fee can easily exceed the drug.
Susvimo, the refillable implant, is a different bill
Susvimo delivers ranibizumab continuously from an implant in the eye, refilled roughly twice a year instead of injected monthly. Its drug bills under a separate code, J2779 at $73.542 per 0.1 mg, and the surgical procedures to implant and refill it are billed separately from CPT 67028. If you are considering it, ask for an itemized estimate covering the implant surgery, the refill procedures, and the drug, rather than comparing it to an injection price.
How to Pay Less
Ask which product, and ask about the brand
At the moment brand Lucentis is the cheapest of the three ranibizumab products to Medicare, by a wide margin. That is unusual and it may not last, but today it is worth $223 a visit against Byooviz.
Uninsured or underinsured: the free drug program
Lucentis is a Genentech product, and the Genentech Patient Foundation supplies Genentech drugs free to patients who qualify on income, with no citizenship requirement, shipped to your retina clinic: (888) 941-3331. Income-tested and not guaranteed, but it is the largest lever available.
Medicare: a charity fund, not a copay card
Manufacturer copay assistance is not legally available to Medicare patients. Independent foundations with macular degeneration or retinal disease funds are: the PAN Foundation, HealthWell Foundation, and Good Days. Apply the day you find one open, because they close when funding runs out. Our medication assistance checker routes by coverage type.
Already have the bill
If the charge looks nothing like the numbers above, something is probably wrong with the code, the units, or the eye modifier. CareRoute Bill Defense reviews it and negotiates. Free to submit, and you only pay if we reduce it.
Frequently Asked Questions
How much does Lucentis cost per injection?
Medicare's payment limit for October through December 2026 is $26.384 per 0.1 mg of ranibizumab (code J2778). The wet macular degeneration dose of 0.5 mg is 5 units, so the drug is allowed $131.92. Adding $114.23 for the injection in a doctor's office brings a visit to $246.15, and your 20% on Original Medicare is $49.23. The 0.3 mg diabetic eye disease dose is 3 units, $79.15 of drug, $193.38 in total, and $38.68 to you.
Why did Lucentis get so much cheaper?
A Medicare Part B payment limit tracks the drug's actual average selling price, recalculated every quarter, not its list price. As ranibizumab lost volume to Eylea, Vabysmo, and its own biosimilars, its reported selling price fell and the limit followed it down: $65.443 per unit in January 2026, $67.853 in April, $51.090 in July, and $26.384 in October. It will be recalculated again for January 2027.
Is the Lucentis biosimilar cheaper than Lucentis?
Not right now, and the gap is large. In the October 2026 file brand Lucentis is $26.384 per 0.1 mg, Cimerli is $81.130, and Byooviz is $249.493. For the same 0.5 mg dose that is $131.92 against $405.65 and $1,247.47 of drug, so your 20% is $26.38, $81.13, or $249.49. The brand's price fell faster than the biosimilars'. Check which code appears on your claim, and ask the practice which product they bill.
How many units of J2778 should my bill show?
Five units for a 0.5 mg dose (wet macular degeneration, retinal vein occlusion) and three units for a 0.3 mg dose (diabetic macular edema, diabetic retinopathy), per eye. CPT 67028 should appear once per eye with an RT or LT modifier, or modifier 50 if both eyes were injected at the same visit. A claim showing 50 units instead of 5 is a decimal error worth about $1,187.
What does a year of Lucentis cost?
At six injections a year in one eye, Medicare's allowed total is $1,476.90 and your 20% is $295.38. For comparison, the same six injections cost you about $1,870 on Eylea and $2,392 on Vabysmo. Double if both eyes are treated. Part B has no annual out-of-pocket maximum, so unless you have a Medigap policy, a Medicare Advantage plan, retiree coverage, or Medicaid, your 20% continues indefinitely.
Does Medicare cover Lucentis?
Yes, under Part B rather than a Part D drug plan, because a clinician injects it. Part B pays 80% of the allowed amount after the 2026 annual deductible of $283. Medicare Advantage plans cover it too but may require prior authorization or step therapy through bevacizumab or another agent first, and an unapproved step is a common reason a covered injection turns into a full-price bill.
Related Guides
Sources
- CMS, October 2026 Medicare Part B Payment Limit File (ASP pricing file), effective October 1 to December 31, 2026, based on 2Q26 ASP data: J2778 $26.384, Q5124 $249.493, Q5128 $81.130, J2779 $73.542, all per 0.1 mg. January ($65.443), April ($67.853), and July ($51.090) 2026 files for the J2778 trend.
- CMS, 2026 National Physician Fee Schedule Relative Value File (October release): CPT 67028, 3.42 non-facility and 2.26 facility total RVUs, conversion factor $33.4009.
- FDA prescribing information for Lucentis (ranibizumab): 0.5 mg for wet AMD and retinal vein occlusion, 0.3 mg for diabetic macular edema and diabetic retinopathy.
- Genentech Patient Foundation program terms, verified free-drug eligibility and intake line (888) 941-3331.
- CMS, 2026 Medicare Parts A and B premiums and deductibles (Part B deductible $283).
Medicare payment limits are republished quarterly and ranibizumab's has been moving fast; these are the October to December 2026 figures. Commercial plans pay their own negotiated rates. Which drug and which product is right for you is a decision for you and your retina specialist. This is cost information, not medical advice. Last updated November 12, 2026.